Status
Conditions
About
Background:
Objectives:
Eligibility:
Design:
Full description
Background:
A mammography facility in the Clinical Center of the National Institutes of Health (NIH) is present in order to facilitate breast cancer research programs. The American College of Radiology mammography accreditation program (1992 mammography Quality Standards Act (MQSA) (1-3)) has established national standards for site accreditation for mammography. A key requirement is to perform a minimum number of mammography examinations in the facility per year. Minimum examination volumes are required to maintain expertise of the facility staff for maintaining facility accreditation and compliance with Food and Drug Administration (FDA) requirements.
Objectives:
Our primary aim is a protocol to maintain accreditation of the NIH breast imaging facility in the Clinical Center of NIH.
Eligibility:
Women who are clinically indicated for screening mammography according to the National Comprehensive Cancer Network (NCCN) guidelines (3) and the American Cancer Society guidelines.
Design:
A standard of care protocol to perform standard clinically indicated mammography exams. We are expected to recruit 1000 patient /year.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Women who are clinically indicated for screening mammography according to the National Comprehensive Cancer Network (NCCN) guidelines (3) and the American Cancer Society guidelines:
All women who fall under the ACS mammography guidelines
Women younger than 40 years but with more than 20% lifetime risk for developing breast cancer:
i. First degree relative diagnosed with breast, ovarian, fallopian tube, or primary peritoneal cancer.
ii. Individual from families known to have BRCA 1 or 2 gene mutation.
iii. Close male blood relative with breast cancer.
d. Genetic predisposition;
i. Carry or have first-degree relative who carries a genetic mutation in the BRCA 1 or 2 genes.
ii. Carry or have a first-degree relative who carries a genetic mutation in the TP53 or PTEN genes (Li-Fraumeni syndrome and Cowden Bannayan-Riley-Ruvalcaba syndromes).
e. A personal history of Lobular carcinoma in situ (LCIS) and/or atypical ductal hyperplasia (ADH)
f. Prior personal history of breast cancer or ovarian cancer.
i. Starting at the age of 25 year for Hereditary breast and ovarian cancer patients.
ii. 5-10 years prior to youngest breast cancer case for strong family history or other genetic predisposition.
g. Woman and Minorities
EXCLUSION CRITERIA:
Pregnant or lactating subjects.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal